The recombinant dna technology global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Recombinant DNA Technology Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The recombinant dna technology market size has grown strongly in recent years. It will grow from <b>$816.9 billion in 2023 to $882.04 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. </b> The growth in the historic period can be attributed to healthcare demands, biopharmaceutical industry growth, rising investments in r&d, emergence of personalized medicine.
The recombinant dna technology market size is expected to see strong growth in the next few years. It will grow to <b>$1214.85 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. </b> The growth in the forecast period can be attributed to rising chronic diseases, emerging biotech startups, increasing funding in biotech, globalization of biotech markets, consumer acceptance and education. Major trends in the forecast period include scientific advancements, gene editing advancements, cell and gene therapies, development of rna therapeutics, therapeutic applications in rare diseases, ai and data integration.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report
Scope Of Recombinant DNA Technology Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Recombinant DNA Technology Market Overview
Market Drivers –
The increasing number of chronic diseases is expected to propel the growth of the recombinant DNA technology market. Chronic diseases, which are defined as ailments that last for a year or longer, necessitate continuing medical care, restrict everyday activities, or both. Recombinant DNA technology has improved healthcare by creating biopharmaceuticals proteins used in pharmaceuticals and by replacing defective genes with healthy ones through gene therapy, aiming to cure illness. For instance, in April 2021, according to a report shared by WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, noncommunicable diseases (NCDs) accounted for 41 million annual deaths, or 71% of all deaths worldwide. Between the ages of 30 and 69, more than 15 million people per year die from an NCD; 85% of these premature deaths take place in low- and middle-income nations. Therefore, the increase in chronic diseases is driving the growth of the recombinant DNA technology market.
Market Trends –
Technological advancement is a key trend in the recombinant DNA technology market. Major companies operating in the recombinant DNA technology market are focused on innovative technologies to sustain their position in the market. For instance, in October 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents and consumables, and software services, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) equipment made to deliver extremely precise and reliable findings in genetic analysis and research in less than 90 minutes. The QuantStudio Absolute Q System uses microfluidic array technology and streamlined processes instead of the complicated, multi-instrument workflows necessary for standard dPCR, which is intended to increase data accuracy and consistency. The QuantStudio Absolute Q solution is a quick and easy workflow that provides high-quality data with the least amount of manual labour. It combines the data collection, heat cycling, and digitization processes required for dPCR into a single device.
The recombinant dna technology market covered in this report is segmented –
1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types
Get an inside scoop of the recombinant dna technology market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp
Regional Insights –
North America was the largest region in the recombinant DNA technology market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the recombinant dna technology market report are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline plc, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam plc, Horizon Discovery Group plc, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.
Table of Contents
1. Executive Summary
2. Recombinant DNA Technology Market Report Structure
3. Recombinant DNA Technology Market Trends And Strategies
4. Recombinant DNA Technology Market – Macro Economic Scenario
5. Global Recombinant DNA Technology Market Size and Growth
.
.
.
31. Global Recombinant DNA Technology Market Competitive Benchmarking
32. Global Recombinant DNA Technology Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Recombinant DNA Technology Market
34. Recombinant DNA Technology Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
